Evidence map›Paper›PMID 40383762›Full record

ReviewEuropean journal of medical research2025

Dual role of miR-155 and exosomal miR-155 in tumor angiogenesis: implications for cancer progression and therapy.

Qusay Mohammed Hussain, Ali Fawzi Al-Hussainy, Gaurav Sanghvi, R Roopashree, Aditya Kashyap, D Alex Anand, Rajashree Panigrahi, Nargiz Shavazi, Sada Ghalib Taher, Mariem Alwan and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qusay Mohammed HussainCollege of Pharmacy, Alnoor University, Mosul, Iraq. qusay.mohammed@alnoor.edu.iq.
Ali Fawzi Al-HussainyCollege of Pharmacy, Ahl Al Bayt University, Kerbala, Iraq.
Gaurav SanghviMarwadi University Research Center, Department of Microbiology, Faculty of Science, Marwadi University, Rajkot, Gujarat, 360003, India.
R RoopashreeDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Aditya KashyapCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
D Alex AnandDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Rajashree PanigrahiDepartment of Microbiology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Nargiz ShavaziDepartment of Obstetrics and Gynecology, Samarkand State Medical University, Samarkand, Uzbekistan.
Sada Ghalib TaherCollege of Dentistry, University of Thi-Qar, Thi-Qar, 64001, Iraq.
Mariem AlwanPharmacy College, Al-Farahidi University, Baghdad, Iraq.
Mahmood JawadDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Hiba MushtaqGilgamesh Ahliya University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor angiogenesis facilitates cancer progression by supporting tumor growth and metastasis. MicroRNA-155 (miR-155) plays a pivotal role in regulating angiogenesis through both direct effects on tumor and endothelial cells and indirect modulation via exosomal communication. This review highlights miR-155's pro-angiogenic influence on endothelial cell behavior and tumor microenvironment remodeling. Additionally, exosomal miR-155 enhances intercellular communication, promoting vascularization in several cancers. Emerging therapeutic strategies include miR-155 inhibition using antagomirs, exosome-mediated delivery systems, and modulation of pathways such as JAK2/STAT3 and TGF-β/SMAD2. Targeting miR-155 represents a promising approach to hinder tumor angiogenesis and improve cancer therapy outcomes.

Indexed as

ExosomesMicroRNAsNeoplasmsNeovascularization, PathologicAngiogenesisAnimalsDisease ProgressionHumansTumor MicroenvironmentMicroRNAsMIRN155 microRNA, humanAngiogenesisCancerExosomeMicroRNA-155

Identifiers

PMID40383762
PMCPMC12087080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.